When it comes to CLL/SLL treatment, what’s the difference between BTK inhibitors and BCL-2 inhibitors? Understanding how these treatment approaches work and how they fit into the treatment…
BTK degrader BGB-16673 reduced tumor burden in 85% of patients from a high-risk, hard-to-treat group with relapsed / refractory CLL. Dr. Stephan Stilgenbauer from Ulm University and colleagues…
In this review published in Nutrients, the authors discuss the importance of magnesium for the immune system and in the setting of infectious diseases. Reduced magnesium intake has…
In a study of 16,331 patients in the California Cancer Registry, 5.7% developed a second primary malignancy more than 1 year after diagnosis. The 10-year cumulative incidence of…
Jolan Walter, MD, PhD, division chief of the University of South Florida (USF) and Johns Hopkins All Children’s Pediatric Allergy & Immunology Programs, discusses the importance of long-term…
In this HemaSphere review, researchers share details about recent progress related to gene therapy technologies and procedures for primary immunodeficiency. Transduction of hematopoietic stem cells using lentiviral vectors…
In a study designed to investigate the biological relevance of PARP1 in multiple myeloma (MM), data revealed a significant correlation between increased PARP1 mRNA expression and poor prognosis…
In a study designed to analyze and improve the diagnostic sensitivity and specificity of the immunodeficiency disease-related scoring system in adult patients referred to immunology with clinical suspicion…
Corey Cutler, MD, MPH, medical director of the Adult Stem Cell Transplantation Center at Dana-Farber Cancer Institute, discusses Blood and Marrow Clinical Trials Network Study 1102, comparing patients…
Phase 3 ASCERTAIN Trial Shows Promising Results with Oral Decitabine and Cedazuridine Combination for the Treatment of Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia
Naval Daver, MD, University of Texas MD Anderson Cancer Center, shares recent work on combination magrolimab, a CD47-targeting monoclonal antibody, and the hypomethylating agent azacitidine. The azacitidine and…
Sergio Rutella, MD, PhD, FRCPath, hematologist and professor of cancer immunotherapy at the John van Geest Cancer Research Centre, reports new findings from his work on acute myeloid…
